<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177891</url>
  </required_header>
  <id_info>
    <org_study_id>AOM08084</org_study_id>
    <nct_id>NCT01177891</nct_id>
  </id_info>
  <brief_title>Genetic Analysis of Familial Cases of Premature Ovarian Failure</brief_title>
  <acronym>FAMIOP</acronym>
  <official_title>Genetic Analysis of Familial Cases of Premature Ovarian Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Premature ovarian failure (POF) is a rare syndrome observed in women under 40 who induced
      estrogen deficiency and often leads to infertility final. The etiologies of POF remain
      unknown in more than 85% of cases. There are 5-10 % of familial cases.The main objective of
      this study is to recruit, phenotype and genotype 20 families with at least two subjects with
      nonsyndromic POF in order to identify new loci using a single technical standard nucleotide
      polymorphisms (SNPs). This study will also include related population and population control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It was decided to move towards a study of familial cases of IOP. This study will identify
      areas of susceptibility in new families, identify candidate genes, sequence these genes in
      cases familial POF and sporadic cases in order to detect potential mutations, and in the
      control population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of candidate regions by genotyping within families</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Familial Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Subject index</arm_group_label>
    <description>Population of familial cases of POF : 20 families with at least two subjects with POF nonsyndromic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population Index Related topics</arm_group_label>
    <description>Women, healthy women, men are potential carriers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Population control</arm_group_label>
    <description>100 Caucasian women with normal cycles until at least the age of 40 years and a proven fertility</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Caucasian population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients of familial cases of POF :

          -  Female subjects between 16 and 40 years or women older than 40 years with a cessation
             of ovarian function before the age of 40 years with increased levels of FSH

          -  Primary or secondary amenorrhea for more than three months with LH and FSH&gt; 30mUI/ml

          -  No cases of fragile X syndrome in the family or blepharophimosis syndrome

          -  At least two cases in the family

          -  Origin Caucasian

          -  Patient signing the consent form for at least the blood sample

          -  Patient with Social Security

        Population Index related topics :

          -  The presence of cycles until the age of 40 years with proven fertility, at least one
             child

          -  Amenorrhea and FSH&gt; 30mUI/ml according to the criteria of the index subject

          -  Men of the family of index case

        Population control :

          -  Women of Caucasian origin

          -  Women who had regular cycles until at least age 40 and at least one child

          -  Lack of land autoimmune (no history of thyroid disease or diabetes type 1)

          -  Woman signing the consent form for at least the blood sample

        Exclusion Criteria:

          -  Blood donation of more than 450ml in the previous three months.

          -  Subject with an abnormal karyotype in favor of Turner syndrome or having a premutation
             of the FMR1 gene or a syndromic form

          -  Subject exclusion period in another study without direct individual benefit

          -  Subject refusing to sign the consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Christin-Maitre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Antoine hospital, Service of Endocrinology, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Saint-Antoine, Endocrinology service</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophie Christin-Maitre</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Lebedin YS, Gorchakov VD, Petrova EN, Kobylyansky AG, Raudla LA, Tatarsky AR, Bobkov EV, Adamova IY, Vasilov RG, Nasonov EL, et al. Ex vivo removal of IgE in atopic asthma by extracorporeal plasmoimmunoadsorption (EPIA): development of a clinical adsorbent. Int J Artif Organs. 1991 Aug;14(8):508-14.</citation>
    <PMID>1937940</PMID>
  </reference>
  <reference>
    <citation>Knauff EA, Franke L, van Es MA, van den Berg LH, van der Schouw YT, Laven JS, Lambalk CB, Hoek A, Goverde AJ, Christin-Maitre S, Hsueh AJ, Wijmenga C, Fauser BC; Dutch POF Consortium. Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. Hum Reprod. 2009 Sep;24(9):2372-8. doi: 10.1093/humrep/dep197. Epub 2009 Jun 9.</citation>
    <PMID>19508998</PMID>
  </reference>
  <reference>
    <citation>Charbit B, Christin-Maître S, Démolis JL, Soustre E, Young J, Funck-Brentano C. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol. 2009 Mar 15;103(6):887-90. doi: 10.1016/j.amjcard.2008.11.041. Epub 2009 Jan 24.</citation>
    <PMID>19268751</PMID>
  </reference>
  <reference>
    <citation>Rousseau A, Ayoubi F, Deveaux C, Charbit B, Delmau C, Christin-Maitre S, Jaillon P, Uzan G, Simon T. Impact of age and gender interaction on circulating endothelial progenitor cells in healthy subjects. Fertil Steril. 2010 Feb;93(3):843-6. doi: 10.1016/j.fertnstert.2008.10.062. Epub 2008 Dec 25.</citation>
    <PMID>19111297</PMID>
  </reference>
  <reference>
    <citation>Warcoin M, Lespinasse J, Despouy G, Dubois d'Enghien C, Laugé A, Portnoï MF, Christin-Maitre S, Stoppa-Lyonnet D, Stern MH. Fertility defects revealing germline biallelic nonsense NBN mutations. Hum Mutat. 2009 Mar;30(3):424-30. doi: 10.1002/humu.20904.</citation>
    <PMID>19105185</PMID>
  </reference>
  <reference>
    <citation>Madelenat P, Koskas M; Groupe de réflexion sur la contraception progestative. [Update on the progestin-only contraception]. J Gynecol Obstet Biol Reprod (Paris). 2008 Nov;37(7):637-60. doi: 10.1016/j.jgyn.2008.06.013. Epub 2008 Sep 27. French.</citation>
    <PMID>18824306</PMID>
  </reference>
  <reference>
    <citation>Beysen D, De Jaegere S, Amor D, Bouchard P, Christin-Maitre S, Fellous M, Touraine P, Grix AW, Hennekam R, Meire F, Oyen N, Wilson LC, Barel D, Clayton-Smith J, de Ravel T, Decock C, Delbeke P, Ensenauer R, Ebinger F, Gillessen-Kaesbach G, Hendriks Y, Kimonis V, Laframboise R, Laissue P, Leppig K, Leroy BP, Miller DT, Mowat D, Neumann L, Plomp A, Van Regemorter N, Wieczorek D, Veitia RA, De Paepe A, De Baere E. Identification of 34 novel and 56 known FOXL2 mutations in patients with Blepharophimosis syndrome. Hum Mutat. 2008 Nov;29(11):E205-19. doi: 10.1002/humu.20819.</citation>
    <PMID>18642388</PMID>
  </reference>
  <reference>
    <citation>Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, Christin-Maître S, Bouvattier C, Raux-Demay MC, Bouchard P, Carel JC, Leger J, Kuttenn F, Polak M, Touraine P; Centre des Maladies Endocriniennes Rares de la Croissance and Association Surrénales. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2008 Jun;158(6):879-87. doi: 10.1530/EJE-07-0887. Epub 2008 Apr 7.</citation>
    <PMID>18390993</PMID>
  </reference>
  <reference>
    <citation>Christin-Maitre S. [Physiology of ovulation and mode of action of contraceptive pills]. Rev Prat. 2008 Jan 15;58(1):17-20. Review. French.</citation>
    <PMID>18326357</PMID>
  </reference>
  <reference>
    <citation>Christin-Maitre S. The role of hormone replacement therapy in the management of premature ovarian failure. Nat Clin Pract Endocrinol Metab. 2008 Feb;4(2):60-1. Epub 2007 Nov 20. Review.</citation>
    <PMID>18030288</PMID>
  </reference>
  <reference>
    <citation>Tachdjian G, Aboura A, Portnoï MF, Pasquier M, Bourcigaux N, Simon T, Rousseau G, Finkel L, Benkhalifa M, Christin-Maitre S. Cryptic Xp duplication including the SHOX gene in a woman with 46,X, del(X)(q21.31) and premature ovarian failure. Hum Reprod. 2008 Jan;23(1):222-6. Epub 2007 Nov 1.</citation>
    <PMID>17981816</PMID>
  </reference>
  <reference>
    <citation>Vinci G, Christin-Maitre S, Pasquier M, Bouchard P, Fellous M, Veitia RA. FOXO3a variants in patients with premature ovarian failure. Clin Endocrinol (Oxf). 2008 Mar;68(3):495-7. Epub 2007 Sep 19.</citation>
    <PMID>17888023</PMID>
  </reference>
  <reference>
    <citation>Laissue P, Christin-Maitre S, Bouchard P, Fellous M, Veitia RA. Mutations in the NOG gene are not a common cause of nonsyndromic premature ovarian failure. Clin Endocrinol (Oxf). 2007 Jun;66(6):900. Epub 2007 Mar 23.</citation>
    <PMID>17381491</PMID>
  </reference>
  <reference>
    <citation>Zanotti-Fregonara P, Khoury A, Duron F, Keller I, Christin-Maître S, Kiffel T, Toubert ME, Devaux JY, Hindié E. Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):541-6. Epub 2006 Nov 14.</citation>
    <PMID>17106700</PMID>
  </reference>
  <reference>
    <citation>Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S, Cortet B, Costagliola D, Diebolt V, Lacoin F, Letombe B, Oberlin F, Orcel P, Ravaud P, Seret P, Thomas T, Vogel JY, Barna A, Nouyrigat E, Veyries ML, Yoldjian I. [Drug treatment of postmenopausal osteoporosis. What's New in 2006]. Presse Med. 2006 Oct;35(10 Pt 2):1529-39. Review. French.</citation>
    <PMID>17028517</PMID>
  </reference>
  <reference>
    <citation>Laissue P, Christin-Maitre S, Touraine P, Kuttenn F, Ritvos O, Aittomaki K, Bourcigaux N, Jacquesson L, Bouchard P, Frydman R, Dewailly D, Reyss AC, Jeffery L, Bachelot A, Massin N, Fellous M, Veitia RA. Mutations and sequence variants in GDF9 and BMP15 in patients with premature ovarian failure. Eur J Endocrinol. 2006 May;154(5):739-44.</citation>
    <PMID>16645022</PMID>
  </reference>
  <reference>
    <citation>De Baere E, Copelli S, Caburet S, Laissue P, Beysen D, Christin-Maitre S, Bouchard P, Veitia R, Fellous M. Premature ovarian failure and forkhead transcription factor FOXL2: blepharophimosis-ptosis-epicanthus inversus syndrome and ovarian dysfunction. Pediatr Endocrinol Rev. 2005 Jun;2(4):653-60. Review.</citation>
    <PMID>16208278</PMID>
  </reference>
  <reference>
    <citation>Christin-Maitre S, Duron F. Fetal loss associated with excess thyroid hormone exposure. JAMA. 2004 Nov 3;292(17):2085-6; author reply 2086.</citation>
    <PMID>15523067</PMID>
  </reference>
  <reference>
    <citation>Ouzounian S, Christin-Maitre S. [What is menopause?]. Rev Prat. 2005 Feb 28;55(4):363-8. Review. French.</citation>
    <PMID>15828613</PMID>
  </reference>
  <reference>
    <citation>Simon T, Boutouyrie P, Gompel A, Christin-Maitre S, Laurent S, Thuillez C, Zannad F, Bernaud C, Jaillon P; CASHMERE investigators. Rationale, design and methods of the CASHMERE study. Fundam Clin Pharmacol. 2004 Feb;18(1):131-8.</citation>
    <PMID>14748765</PMID>
  </reference>
  <reference>
    <citation>Hulot JS, Démolis JL, Rivière R, Strabach S, Christin-Maitre S, Funck-Brentano C. Influence of endogenous oestrogens on QT interval duration. Eur Heart J. 2003 Sep;24(18):1663-7.</citation>
    <PMID>14499229</PMID>
  </reference>
  <reference>
    <citation>Christin-Maitre S, Ronci-Chaix N, Bouchard P. [Ovary genes and molecular pathology]. J Soc Biol. 2002;196(3):207-16. Review. French.</citation>
    <PMID>12462074</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2010</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

